Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLINICAL-PHARMACOLOGY AND TISSUE DISPOSITION STUDIES OF I-131-LABELEDANTICOLORECTAL CARCINOMA HUMAN MONOCLONAL-ANTIBODY LICO-16.88
Autore:
ROSENBLUM MG; LEVIN B; ROH M; HOHN D; MCCABE R; THOMPSON L; CHEUNG L; MURRAY JL;
Indirizzi:
UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,IMMUNOPHARMACOL SECT HOUSTON TX 77030 UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL HOUSTON TX 00000 UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT GEN SURG HOUSTON TX 77030 UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,EXPTL IMMUNOTHERAPY SECT HOUSTON TX 77030 BIONET RES INST ROCKVILLE MD 20859
Titolo Testata:
Cancer immunology and immunotherapy
fascicolo: 6, volume: 39, anno: 1994,
pagine: 397 - 400
SICI:
0340-7004(1994)39:6<397:CATDSO>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLORECTAL-CANCER; IMMUNE-RESPONSE; TUMOR UPTAKE; PHARMACOKINETICS; RADIOIMMUNOTHERAPY; IMMUNOGENICITY; TOXICITY;
Keywords:
HUMAN IGM; CLINICAL PHARMACOLOGY; RADIOLABELED ANTIBODIES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
21
Recensione:
Indirizzi per estratti:
Citazione:
M.G. Rosenblum et al., "CLINICAL-PHARMACOLOGY AND TISSUE DISPOSITION STUDIES OF I-131-LABELEDANTICOLORECTAL CARCINOMA HUMAN MONOCLONAL-ANTIBODY LICO-16.88", Cancer immunology and immunotherapy, 39(6), 1994, pp. 397-400

Abstract

Antibody LiCO 16.88 is a human IgM recognizing a 30- to 45-kDa intracytoplasmic antigen present in human adenocarcinoma cells. An 8-mg sample of antibody labeled with 5 mCi I-131 was co-administered i. v. with120 mg (three patients), 240 mg (three patients) or 480 mg (four patients) unlabeled antibody as a 4-h infusion. The plasma half-life was 24+/-1.2 h and the immediate apparent volume of distribution was 5.2+/-0.2 1 at the 28-mg dose level. The plasma half-lives and the cumulative urinary excretion of radiolabel did not seem to vary significantly with increasing doses of unlabeled antibody. However, both the volume of distribution and the clearance rate from plasma increased significantly with increasing antibody dose. Uptake of antibody into tumor tissues obtained during laparotomy 8-9 days after administration varied between 0.00002% ID/g and 0.00127% ID/g. In five of seven patients, the tumor content of antibody was higher than that in adjacent normal tissue. Tumor-to-normal tissue ratios ranged from 0.8 to 10 (($) over bar x= 3.8+/-1.0). In general, the higher radioactivity(cpm)/g tumor was confirmed by both immunoperoxidase and autoradiography. Antibody 16.88 localizes in tumors after administration and may be considered for usein radioimmunotherapy trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 15:36:57